On 19 November 2014, orphan designation (EU/3/14/1358) was granted by the European Commission to FGK Representative Service GmbH, Germany, for recombinant human pentraxin-2 for the treatment of post-essential thrombocythaemia myelofibrosis.

The sponsorship was transferred to Roche Registration GmbH, Germany, in June 2020.

Key facts

Active substance
Recombinant human pentraxin-2
Disease / condition
Treatment of post-essential thrombocythaemia myelofibrosis
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Tel. +49 7624 142892

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating